Literature DB >> 1525575

Retroocular fibroblasts: important effector cells in Graves' ophthalmopathy.

R S Bahn1, A E Heufelder.   

Abstract

Retroocular and pretibial fibroblasts are likely important effector cells in Graves' ophthalmopathy and pretibial dermopathy. Histologic similarities exist between the tissues involved in these clinically diverse extrathyroidal manifestations of Graves' disease. Both conditions are characterized by an accumulation of glycosaminoglycans (GAGs) and an infiltration of lymphocytes. We have shown that particular cytokines, probably released by the local inflammatory cell infiltrate, are capable of stimulating GAG synthesis by retroocular and pretibial fibroblasts. In order to explain the site-selective involvement of these anatomically distinct areas in Graves' disease, we sought to identify unique characteristics shared by retroocular and pretibial fibroblasts. We have shown that affected retroocular and pretibial fibroblasts demonstrate an enhanced HLA-DR response to interferon-gamma treatment and that retroocular fibroblasts are especially sensitive to the GAG-stimulating effect of this cytokine. In addition, we have shown that only affected retroocular and pretibial fibroblasts express the 72 kDa heat shock protein. Therefore, affected retroocular and pretibial fibroblasts possess unique immunologic features that may render them more susceptible to the autoimmune process in Graves' disease. Chronic stimulation of fibroblasts by cytokines released in the local inflammatory milieu may result in excessive GAG production by these cells. The accumulation of these hydrophilic mucopolysaccharides, with attendant edema, leads to the clinical manifestations of Graves' ophthalmopathy and pretibial dermopathy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1525575     DOI: 10.1089/thy.1992.2.89

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  8 in total

1.  Serum levels of soluble Fas in patients with Graves' ophthalmopathy.

Authors:  K Ohtsuka; M Hashimoto
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

2.  Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy.

Authors:  I M Wakelkamp; M N Gerding; J W Van Der Meer; M F Prummel; W M Wiersinga
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

3.  The role of thyroid eye disease and other factors in the overcorrection of hypotropia following unilateral adjustable suture recession of the inferior rectus (an American Ophthalmological Society thesis).

Authors:  Natalie C Kerr
Journal:  Trans Am Ophthalmol Soc       Date:  2011-12

Review 4.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 5.  Thyroid eye disease.

Authors:  D H Char
Journal:  Br J Ophthalmol       Date:  1996-10       Impact factor: 4.638

6.  Orbital fibroblast chemokine modulation: effects of dexamethasone and cyclosporin A.

Authors:  M A Burnstine; S G Elner; V M Elner
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

7.  Elevated expression in situ of selectin and immunoglobulin superfamily type adhesion molecules in retroocular connective tissues from patients with Graves' ophthalmopathy.

Authors:  A E Heufelder; R S Bahn
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

8.  MicroRNA-146a downregulates the production of hyaluronic acid and collagen I in Graves' ophthalmopathy orbital fibroblasts.

Authors:  Wei Liu; Chao Ma; Hao-Yu Li; Lan Chen; Shan-Si Yuan; Kai-Jun Li
Journal:  Exp Ther Med       Date:  2020-09-01       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.